Data / Form D filings / Silverback Therapeutics, Inc.
Silverback Therapeutics, Inc.: Form D filings
Silverback Therapeutics, Inc., a biotechnology company in Seattle, WA, filed 8 Form D notices with the SEC between 2016 and 2020. The latest, on October 6, 2020, reports $85 million sold of a $85 million offering to 31 investors.
Find out what Silverback Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 500 FAIRVIEW AVENUE NORTH, SUITE 600, Seattle, WA, 98109
- Phone
- (206) 456-2900
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2016
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1671858
The full lists. Form D filings in Washington: 1,095 rows, $54.75, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 6, 2020 | New notice | $84,999,995 | $84,999,995 | $0 | 31 | Sep 22, 2020 | sec.gov |
| Mar 19, 2020 | New notice | $78,697,259 | $31,754,277 | $46,942,982 | 16 | Mar 4, 2020 | sec.gov |
| Sep 20, 2018 | New notice | $19,999,990 | $12,499,994 | $7,499,996 | 3 | Sep 5, 2018 | sec.gov |
| Jan 8, 2018 | New notice | $3,749 | $3,749 | $0 | 1 | Dec 22, 2017 | sec.gov |
| Feb 6, 2017 | Amendment | $60,000,000 | $10,000,001 | $49,999,999 | 1 | Apr 1, 2016 | sec.gov |
| Nov 30, 2016 | New notice | $25,000 | $0 | $25,000 | 0 | Yet to occur | sec.gov |
| Apr 12, 2016 | New notice | $60,000,000 | $10,000,001 | $49,999,999 | 1 | Apr 1, 2016 | sec.gov |
| Apr 12, 2016 | New notice | $200 | $200 | $0 | 2 | Mar 31, 2016 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jonathan L. Root | Director | |
| Thilo L. Schroeder | Director | |
| Scott L. Platshon | Director | |
| Laura Shawver | Executive Officer, Director | |
| Vickie L. Capps | Director | |
| Robert L. Hershberg | Director | |
| Saqib L. Islam | Director | |
| Peter A. Thompson | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Oct 5, 2020 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Silverback Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.